Skip to main content
Back to all tickers

Aytu BioPharma, Inc. (AYTU) stock forecast & analysis

2.66

NasdaqCM · USDDelayed by 15 minutes

Unchanged: +0.00, +0.0%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for AYTU.US from 10-21 12:00 to 11-19 21:00 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Latest analysis: · verdict locked

Open
2.66
Previous close
2.66
Day range
2.65 – 2.66
52-week range
1.75 – 3.07
Volume (shares)
634.76K
Net assets
Not available
Expense ratio
Not available
Shares outstanding
10.87M
P/E ratio
Not available
Dividend yield
0.00%
Beta
Not available
Market cap
28.91M
Market Scanner’s AI analysis of Aytu BioPharma, Inc. (AYTU), updated November 2026: Aytu BioPharma's all-cash acquisition by Rosemont Pharmaceuticals and fiscal Q1 2027 results drove significant price and volume surges.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Aytu BioPharma, Inc. (AYTU) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

Aytu BioPharma's all-cash acquisition by Rosemont Pharmaceuticals and fiscal Q1 2027 results drove significant price and volume surges.

Recent analyses covered Aytu BioPharma's announcement of an all-cash tender offer from Rosemont Pharmaceuticals, intended to accelerate Rosemont's US expansion. This news coincided with the release of Aytu's fiscal Q1 2027 results. The stock experienced a substantial price increase and a dramatic surge in trading volume following these announcements, reclaiming levels above its 50-day and 200-day moving averages.

AYTU news & sentiment

News reports focused on Aytu BioPharma's acquisition by Rosemont Pharmaceuticals and its fiscal Q1 2027 results. Social media discussion centered on the significant price surge and trading volume following these announcements.

AYTU technical picture

The stock experienced a significant price surge, closing substantially higher and reclaiming levels above its 50-day and 200-day moving averages, which had been in decline. Trading volume dramatically increased, reaching approximately 100 times normal levels, while the price action remained tight within a narrow range following the gap up gap.

Fundamentals

The company's market capitalization was noted at $28.9M, with no dividend payments since late 2020. The analysis covered income statement history, though specific details beyond the fiscal year-end 2026 were not provided in the excerpt.

Factors discussed — upside

  • All-cash tender offer from Rosemont Pharmaceuticals.
  • Significant price increase of 46% in a single session.
  • Trading volume increased approximately 100 times normal levels.
  • Stock price closed above both 50-day and 200-day moving averages.

Factors discussed — risks

  • Previous price decline of approximately 22% from late September to early November.
  • 50-day and 200-day moving averages were previously declining.
  • The catalyst for the initial price decline prior to the acquisition news was unknown.
  • Merger and acquisition
  • Financial results
  • Price action and volume
  • Technical indicators

Summary updated .

AYTU technical indicators

Common technical indicators for AYTU, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average2.04Price above
10-day exponential moving average2.21Price above
Relative strength index (14-day)79.50Overbought
MACD line (12/26/9)0.1017Above its signal line
Bollinger bands (20-day, 2σ)1.42 – 2.57Price above the upper band

Analyses

Recent AYTU.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for Aytu BioPharma, Inc.?
The company's recent analyses highlighted an all-cash tender offer from Rosemont Pharmaceuticals, which drove a significant price increase and a substantial surge in trading volume. The stock's price also moved above key technical indicators, specifically its 50-day and 200-day moving averages.
What are the risks for Aytu BioPharma, Inc.?
Prior to the acquisition news, the company experienced a notable price decline over several weeks, and its key moving averages were trending downwards. The catalyst for this earlier price drop was not identified in the analyses.
Is Aytu BioPharma, Inc. bullish or bearish?
Recent AI analyses of Aytu BioPharma, Inc. examined factors on both sides. Discussed upside: The company's recent analyses highlighted an all-cash tender offer from Rosemont Pharmaceuticals, which drove a significant price increase and a substantial surge in trading volume. The stock's price also moved above key technical indicators, specifically its 50-day and 200-day moving averages. Discussed risks: Prior to the acquisition news, the company experienced a notable price decline over several weeks, and its key moving averages were trending downwards. The catalyst for this earlier price drop was not identified in the analyses. These are descriptive observations, not a recommendation.
What is the latest sentiment on Aytu BioPharma, Inc.?
News reports focused on Aytu BioPharma's acquisition by Rosemont Pharmaceuticals and its fiscal Q1 2027 results. Social media discussion centered on the significant price surge and trading volume following these announcements.
How does Market Scanner analyse Aytu BioPharma, Inc.?
Every analysis of Aytu BioPharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Aytu BioPharma, Inc.?

The company's recent analyses highlighted an all-cash tender offer from Rosemont Pharmaceuticals, which drove a significant price increase and a substantial surge in trading volume. The stock's price also moved above key technical indicators, specifically its 50-day and 200-day moving averages.

What are the risks for Aytu BioPharma, Inc.?

Prior to the acquisition news, the company experienced a notable price decline over several weeks, and its key moving averages were trending downwards. The catalyst for this earlier price drop was not identified in the analyses.

Is Aytu BioPharma, Inc. bullish or bearish?

Recent AI analyses of Aytu BioPharma, Inc. examined factors on both sides. Discussed upside: The company's recent analyses highlighted an all-cash tender offer from Rosemont Pharmaceuticals, which drove a significant price increase and a substantial surge in trading volume. The stock's price also moved above key technical indicators, specifically its 50-day and 200-day moving averages. Discussed risks: Prior to the acquisition news, the company experienced a notable price decline over several weeks, and its key moving averages were trending downwards. The catalyst for this earlier price drop was not identified in the analyses. These are descriptive observations, not a recommendation.

What is the latest sentiment on Aytu BioPharma, Inc.?

News reports focused on Aytu BioPharma's acquisition by Rosemont Pharmaceuticals and its fiscal Q1 2027 results. Social media discussion centered on the significant price surge and trading volume following these announcements.

How does Market Scanner analyse Aytu BioPharma, Inc.?

Every analysis of Aytu BioPharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
claude-medium-v2

Run a fresh AYTU.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 1 earlier report



Most analyzed tickers